Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

20-04-2016 | Pediatric lymphoma | Article

21. Diffuse Large B-Cell Lymphoma in Children and Adolescents (B Mature): Introduction

Authors: Marina K. Servitzoglou, Helen Dana, Apostolos G. Pourtsidis, Fani J. Vlachou, Demetrios N. Exarhos

Publisher: Springer International Publishing

Login to get access

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a mature B-cell neoplasm, which accounts for approximately 10–20 % of paediatric NHL [1]. In fact, this definition represents a morphologically, immunologically and clinically heterogeneous group of lymphoid neoplasms, rather than one entity [2]. In contrast to other childhood NHL, there is no specific genetic feature for DLBCL. The recent WHO classification delineated some newly defined entities on the basis of distinctive clinical, pathologic or biologic features.
Literature
1.
Percy CL, Smith MA, Linet M et al (1999) Lymphomas and reticuloendothelial neoplasms. In: Ries LA, Smith MA, Gurney JG et al (eds) Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995. National Cancer Institute, SEER Program, Bethesda, pp 35–50, NIH Pub.No. 99–4649
2.
Jaffe ES, Harris NL, Stein H et al (2008) Introduction and overview of the classification of the lymphoid neoplasms. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, Lyon, pp 157–166
3.
Stein H, Warnke RA, Chan WC (2008) Diffuse large B-cell lymphoma (DLBCL), NOS. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, Lyon, pp 233–237
4.
Reiter A, Klapper W (2008) Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. Br J Haematol 142(3):329–347CrossRefPubMed
5.
Miles RR, Raphael M, McCarthy K et al (2008) Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal centre subtype: Report of the French-American-British (FAB) international study group. Pediatr Blood Cancer 51(3):369–374CrossRefPubMedPubMedCentral
6.
Oschlies I, Klapper W, Zimmermann M et al (2006) Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-centre type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. Blood 107(10):4047–4052CrossRefPubMed
7.
Campo E, Swerdlow S, Harris N et al (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117(19):5019–5032CrossRefPubMedPubMedCentral
8.
Oschlies I, Burkhardt B, Salaverria I et al (2011) Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. Haematologica 96(2):262–268CrossRefPubMedPubMedCentral
9.
Gerrard M, Waxman I, Sposto R et al (2013) Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy. Blood 121(2):278–285CrossRefPubMedPubMedCentral
10.
Burkhardt B, Oschlies I, Klapper W et al (2011) Non-Hodgkin’s lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. Leukemia 25(1):153–160CrossRefPubMed
11.
Klapper W et al (2012) Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood 119(8):1882–1887CrossRefPubMed
12.
Childhood Non-Hodgkin Lymphoma Treatment (PDQ). www.​cancer.​gov/​types/​lymphoma/​hp/​child-nhl-treatment-pdq
13.
Poirel HA et al (2009) Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. Leukemia 23(2):323–331CrossRefPubMedPubMedCentral
14.
Martelli M et al (2014) [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the international extranodal lymphoma study group IELSG-26 study. J Clin Oncol 32(17):1769–1775CrossRefPubMed
15.
Moskowitz GH et al (2010) Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol 28(11):1896–1903CrossRefPubMedPubMedCentral
16.
Nagle SJ et al (2015) The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma. Cancer Med 4(1):7–15CrossRefPubMedPubMedCentral
17.
Heeren JHM, Croonen AM, Pijnenborg JMA (2008) Primary extranodal marginal zone B-cell lymphoma of the female genital tract: a case report and literature review. Int J Gynecol Path 27:243–246
18.
Ahmad AK, Hui P, Litkouhi B et al (2014) Institutional review of primary non-Hodgkin lymphoma of the female genital tract: a 33-year experience. Int J Gynecol Cancer 24(7):1250–1255CrossRefPubMed
19.
Schoder H, Noy A, Gonen M et al (2005) Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol 23:4643–4651CrossRefPubMed
20.
Coughlan M, Elstrom R (2014) The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy. Cancer Imaging 14:34CrossRefPubMedPubMedCentral
21.
Armitage JO (2012) My treatment approach to patients with diffuse large B-cell lymphoma. Mayo Clin Proc 87(2):161–171CrossRefPubMedPubMedCentral
22.
Glotzbecker MP et al (2006) Primary non-Hodgkin’s lymphoma of bone in children. J Bone Joint Surg Am 88(3):583–594CrossRefPubMed
23.
Zhao XF et al (2007) Pediatric primary bone lymphoma – diffuse large B-cell lymphoma. Morphologic and immunohistochemical characteristics of 10 cases. Am J Clin Pathol 127:47–54CrossRefPubMed
24.
Bhojwani D et al (2015) The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma. Br J Haematol 168(6):845–853CrossRefPubMedPubMedCentral
25.
Qiu L et al (2013) The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin’s lymphoma and non-Hodgkin’s lymphoma. Hell J Nucl Med 16(3):230–236PubMed
26.
Rhodes MM et al (2006) Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol 28(5):300–306CrossRefPubMed
27.
Bakhshi S et al (2012) Pediatric nonlymphoblastic non-Hodgkin lymphoma: baseline, interim, and posttreatment PET/CT versus contrast-enhanced CT for evaluation – a prospective study. Radiology 263(3):956–968CrossRef
28.
Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, Cairo MS (2007) Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 109:2773–2780PubMedPubMedCentral
29.
Kazama H, Teramura M, Yoshinaga K, Masuda A (2012) B-cell lymphoma treated with high-dose chemotherapy rescued by in vivo rituximab-purged autologous stem cells. Case Rep Med 2012:Article ID 957063
30.
Oschlies I, Salaverria I, Mahn F, Meinhardt A, Zimmermann M, Woessmann W, Burkhardt B, Gesk S, Krams M, Reiter A, Siebert R, Klapper W (2010) Pediatric follicular lymphoma – a clinico-pathological study of a population-based series of patients treated within the non-Hodgkin’s Lymphoma – Berlin-Frankfurt-Münster (NHL-BFM) multicenter trials. Haematologica 95:253–259CrossRefPubMedPubMedCentral
31.
Swerdlow SH (2004) Pediatric follicular lymphomas, marginal zone lymphomas, and marginal zone hyperplasia. Am J Clin Pathol 122(Suppl 1):S98–S109PubMed
32.
Louissaint A Jr, Ackerman AM, Dias-Santagata D, Ferry JA, Hochberg EP, Huang MS et al (2012) Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement. Blood 120(12):2395–2404CrossRefPubMed
33.
Attarbaschi A, Beishuizen A, Mann G, Rosolen A, Mori T, Uyttebroeck A, Niggli F, Csoka M, Krenova Z, Mellgren K et al (2013) Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a “watch and wait” strategy after complete resection. Ann Hematol 92(11):1537–1541CrossRefPubMed